At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 100 enrolled
Drug / intervention
Peginterferon Alfa-2A +1 moredrug
Likely dose
Peginterferon Alfa-2A 180 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of the Efficacy and Safety of Pegnano Plus Barivir (Ribavirin) in Treatment-naïve Patients With Chronic Hepatitis C at KienGiang General Hospital
Nanogen Pharmaceutical Biotechnology Joint Stock Company·interventional·Posted Apr 10, 2025·Updated Jun 29, 2025
In Brief
A Phase 4 clinical trial evaluating Peginterferon Alfa-2A and Ribavirin Oral Product for Chronic Hepatitis C. Completed, enrolled 100 participants.
Detailed Summary
This study presents a clinical study on the efficacy and safety of Pegnano combined with Barivir (Ribavirin) in treating treatment-naïve patients with Chronic Hepatitis C at Kien Giang General Hospital. The study aims to provide affordable treatment options while evaluating the virological response and side effects associated with the therapy
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2011
Primary CompletionJan 2013
Study CompletionMar 2013
First PostedApr 2025
TodayJul 2026
First PostedApr 10, 2025
Enrollment StartMar 1, 2011
Primary CompletionJan 21, 2013
Study CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 1.2 years ago
Interventions
Peginterferon Alfa-2Adrug
180 mcg, subcutaneous injection, once weekly
Ribavirin Oral Productdrug
15 mg/kg daily, oral (1200 mg/day for body weight \>80 kg)